<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01997203</url>
  </required_header>
  <id_info>
    <org_study_id>HCV-VD2013</org_study_id>
    <nct_id>NCT01997203</nct_id>
  </id_info>
  <brief_title>Long Term Vitamin D Therapy in HCV Treated Patients</brief_title>
  <acronym>VD-HCV</acronym>
  <official_title>Effect of Long-term Vitamin D Therapy on IL-6, Visfatin and Hyaluronic Acid in Hepatitis C Virus Patients' Assessment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Nadia AbdelAaty AbdelKader</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of hepatitis C virus (HCV) infection was carried out using pegylated interferon
      (PEG-IFN), ribavirin (RBV) and vitamin D (vit D) for 48 weeks in HCV genotypes 4a subjects.
      The purpose of this study is to determine the effect of vitamin D on liver affection in such
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fifty patients study group administered vit D were compared with 50 patients control group
      without vit D. The results showed a significant elevation in vit D levels during the time
      period, and significant reduction on HCV RNA from the 12th wk to reach zero level in 24th wk.
      Interleukin 6 (IL-6), visfatin and hyaluronic acid levels were reduced significantly to reach
      normal values. These concentrations reduction by the effect of vit D on HCV indicated the
      reduction in inflammation, infection and liver cirrhosis and nearly amelioration HCV.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    complete patients samples required
  </why_stopped>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>composite measures of Vitamin D, IL-6, Visfatin and Hyaluronic acid in Hepatitis C Virus Patients under antiviral therapy</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>HCV patients under treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fifty patients study group administered vitamin D were compared with 50 patients control group without vitamin D.
Dose of vitamin D 15,000 IU/week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCV without Vit D</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>vitamin D was given to 50 patients (HCV under treatment)</description>
    <arm_group_label>HCV patients under treatment</arm_group_label>
    <other_name>pegylated interferon</other_name>
    <other_name>ribavirin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic HCV infection (positive HCV Ab more than 6 months)

          -  Treated with pegylated interferon and ribavirin

        Exclusion Criteria:

          -  Coinfection with Hepatitis B or Hepatitis D or Human Immunodeficiency Virus

          -  Previous non response to antiviral therapy.

          -  Other causes of chronic liver diseases as schistosomiasis, Wilson disease and
             alcoholic liver disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dina Sabry</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical biochemistry, Cairo university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed M Tawfic</last_name>
    <role>Study Chair</role>
    <affiliation>Tropical Medicine department, bny swif university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yehia M Korriem</last_name>
    <role>Study Chair</role>
    <affiliation>Tropical Medicine department, bny swif university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nadia A Abdelkader</last_name>
    <role>Study Chair</role>
    <affiliation>Tropical Medicine department, Ain Shams university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amany Y Elkazaz</last_name>
    <role>Study Chair</role>
    <affiliation>Medical Biochemistry, faculty of Medicine Suez Canal University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed Ghussin</last_name>
    <role>Study Chair</role>
    <affiliation>Biochemistry department, faculty of Pharmacology Ghazza University.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tropical Medicine department, Bny swif university</name>
      <address>
        <city>Bny swif</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical biochemistry department, Cairo university</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2013</study_first_submitted>
  <study_first_submitted_qc>November 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2013</study_first_posted>
  <last_update_submitted>November 27, 2013</last_update_submitted>
  <last_update_submitted_qc>November 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Dr. Nadia AbdelAaty AbdelKader</investigator_full_name>
    <investigator_title>Ass. prof. Tropical Medicine - Ain Shams University</investigator_title>
  </responsible_party>
  <keyword>hepatitis C infection</keyword>
  <keyword>vitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

